www.fdanews.com/articles/97168-cel-sci-secures-manufacturing-facility-for-cancer-drug
CEL-SCI Secures Manufacturing Facility for Cancer Drug
August 14, 2007
CEL-SCI entered into an agreement with a biomedical real estate group under which it acquires long-term use of a dedicated manufacturing plant near Baltimore for its cancer drug Multikine. The financial value of this transaction to CEL-SCI is about $15 million.
Genetic Engineering and biotechnology News